[go: up one dir, main page]

HUE043842T2 - RNAi-indukált huntingtin gén szuppresszió - Google Patents

RNAi-indukált huntingtin gén szuppresszió

Info

Publication number
HUE043842T2
HUE043842T2 HUE15817385A HUE15817385A HUE043842T2 HU E043842 T2 HUE043842 T2 HU E043842T2 HU E15817385 A HUE15817385 A HU E15817385A HU E15817385 A HUE15817385 A HU E15817385A HU E043842 T2 HUE043842 T2 HU E043842T2
Authority
HU
Hungary
Prior art keywords
gene suppression
huntingtin gene
rnai induced
induced huntingtin
rnai
Prior art date
Application number
HUE15817385A
Other languages
English (en)
Inventor
Pavlina Stefanova Konstantinova
Jana Miniarikova
Original Assignee
Uniqure Ip Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniqure Ip Bv filed Critical Uniqure Ip Bv
Publication of HUE043842T4 publication Critical patent/HUE043842T4/hu
Publication of HUE043842T2 publication Critical patent/HUE043842T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3519Fusion with another nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/50Biochemical production, i.e. in a transformed host cell
    • C12N2330/51Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE15817385A 2014-12-24 2015-12-23 RNAi-indukált huntingtin gén szuppresszió HUE043842T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14200308 2014-12-24

Publications (2)

Publication Number Publication Date
HUE043842T4 HUE043842T4 (hu) 2019-08-28
HUE043842T2 true HUE043842T2 (hu) 2019-09-30

Family

ID=52282540

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15817385A HUE043842T2 (hu) 2014-12-24 2015-12-23 RNAi-indukált huntingtin gén szuppresszió

Country Status (25)

Country Link
US (4) US10174321B2 (hu)
EP (2) EP3237618B1 (hu)
JP (2) JP6839094B2 (hu)
KR (1) KR102636633B1 (hu)
CN (1) CN108064292B (hu)
AU (1) AU2015370903B2 (hu)
CA (1) CA2971920C (hu)
CO (1) CO2017007335A2 (hu)
CY (1) CY1121733T1 (hu)
DK (1) DK3237618T3 (hu)
EA (1) EA037696B1 (hu)
ES (1) ES2732023T3 (hu)
HK (1) HK1246344B (hu)
HR (1) HRP20190992T1 (hu)
HU (1) HUE043842T2 (hu)
IL (1) IL252990B (hu)
LT (1) LT3237618T (hu)
MX (1) MX2017008500A (hu)
PL (1) PL3237618T3 (hu)
PT (1) PT3237618T (hu)
RS (1) RS58862B1 (hu)
SI (1) SI3237618T1 (hu)
SM (1) SMT201900347T1 (hu)
TR (1) TR201908969T4 (hu)
WO (1) WO2016102664A1 (hu)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2572826C2 (ru) 2008-12-02 2016-01-20 Чиралджен, Лтд. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
SG10201403841QA (en) 2009-07-06 2014-09-26 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
BR112015000784A8 (pt) 2012-07-13 2018-04-03 Wave Life Sciences Japan Grupo auxiliar assimétrico
MX356830B (es) 2012-07-13 2018-06-15 Shin Nippon Biomedical Laboratories Ltd Adyuvante de acido nucleico quiral.
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
CN112410339A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
JP2017535266A (ja) 2014-11-14 2017-11-30 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. 筋萎縮性側索硬化症(als)を治療する組成物および方法
HUE043842T2 (hu) * 2014-12-24 2019-09-30 Uniqure Ip Bv RNAi-indukált huntingtin gén szuppresszió
NZ772770A (en) 2015-02-10 2024-10-25 Genzyme Corp Variant rnai
WO2016161388A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Fully stabilized asymmetric sirna
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
AU2016366694C1 (en) 2015-12-10 2021-03-25 Ptc Therapeutics, Inc. Methods for treating huntington's disease
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
EP3458589A4 (en) 2016-05-18 2020-01-01 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
US10457940B2 (en) * 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
JP7376471B2 (ja) 2017-06-05 2023-11-08 ピーティーシー セラピューティクス, インコーポレイテッド ハンチントン病を処置するための化合物
JP7406793B2 (ja) 2017-06-23 2023-12-28 ユニバーシティー オブ マサチューセッツ 2テイル自己デリバリー型siRNAおよび関連方法
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
CN111356763B (zh) * 2017-09-22 2024-03-12 建新公司 变体RNAi
JP7502991B2 (ja) 2017-10-16 2024-06-19 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症(als)の治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
CN108384803A (zh) * 2017-12-19 2018-08-10 上海百力格生物技术有限公司 一种用于miRNA干扰载体构建筛选特异对照的质粒及其构建方法
CN112135815A (zh) 2018-03-27 2020-12-25 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
EP3793566A4 (en) * 2018-05-15 2022-03-16 University of Washington Compositions and methods for reducing spliceopathy and treating rna dominance disorders
EP3794125A4 (en) * 2018-05-15 2022-07-13 University of Massachusetts MODIFIED AAV CONSTRUCTS AND USES THEREOF
WO2020005873A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
EA202092899A1 (ru) 2018-06-27 2021-05-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероарильные соединения для лечения болезни гентингтона
EP3818161A1 (en) 2018-07-02 2021-05-12 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
EP3850098A1 (en) 2018-09-12 2021-07-21 uniQure IP B.V. Rnai induced c9orf72 suppression for the treatment of als/ftd
WO2020104469A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. Method and means to deliver mirna to target cells
AU2019385598A1 (en) 2018-11-19 2021-06-03 Uniqure Ip B.V. RNAi induced reduction of ataxin-3 for the treatment of Spinocerebellar ataxia type 3
EP3884067A1 (en) 2018-11-19 2021-09-29 uniQure IP B.V. A companion diagnostic to monitor the effects of gene therapy
BR112021013109A2 (pt) * 2019-01-09 2021-10-13 Universidade De Coimbra Rna de fita dupla e seus usos.
US11492619B2 (en) 2019-01-18 2022-11-08 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
US20220251567A1 (en) 2019-07-10 2022-08-11 Inserm (Institut National De La Santè Et De La Recherche Médicale) Methods for the treatment of epilepsy
AU2020329155A1 (en) 2019-08-09 2022-03-10 University Of Massachusetts Chemically modified oligonucleotides targeting SNPs
WO2021053018A1 (en) 2019-09-16 2021-03-25 Uniqure Ip B.V. Targeting misspliced transcripts in genetic disorders
KR20220094213A (ko) * 2019-11-01 2022-07-05 알닐람 파마슈티칼스 인코포레이티드 헌팅틴 (HTT) iRNA 제제 조성물 및 이의 사용 방법
EP4051280A1 (en) 2019-11-01 2022-09-07 Novartis AG The use of a splicing modulator for a treatment slowing progression of huntington's disease
JP2023521347A (ja) * 2020-04-07 2023-05-24 ユニキュアー アイピー ビー.ブイ. アンジオポエチン様3(angptl3)をサイレンシングするための遺伝子構築物及びその使用
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
US20220090069A1 (en) * 2020-08-03 2022-03-24 University Of Massachusetts Oligonucleotides for htt-1a modulation
CN117203336A (zh) 2021-03-29 2023-12-08 阿尔尼拉姆医药品有限公司 亨廷顿蛋白(HTT)iRNA药剂组合物以及其使用方法
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
EP4317434A1 (en) * 2021-03-30 2024-02-07 Nanjing University Rna delivery system for treatment of huntington's disease
WO2022268835A1 (en) 2021-06-21 2022-12-29 Uniqure Biopharma B.V. Gene constructs for silencing alpha-synuclein and uses thereof
JP2025503910A (ja) * 2022-01-27 2025-02-06 アスクレピオス バイオファーマシューティカル, インコーポレイテッド 神経疾患を処置するための組成物
EP4508214A1 (en) 2022-04-12 2025-02-19 uniQure biopharma B.V. Nucleic acid regulation of c9orf72
CN119032174A (zh) 2022-04-12 2024-11-26 优尼科生物制药有限公司 ApoE的核酸调节
WO2023198662A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Novel systems for nucleic acid regulation
EP4508216A1 (en) 2022-04-12 2025-02-19 uniQure biopharma B.V. Nucleic acid regulation of snca
WO2024218204A1 (en) 2023-04-18 2024-10-24 Uniqure Biopharma B.V. Gene delivery vehicles comprising rna and antibodies
WO2025051805A1 (en) 2023-09-04 2025-03-13 Uniqure Biopharma B.V. Novel neurotropic recombinant adeno-associated virus particles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101787A1 (ja) 2003-05-14 2004-11-25 Japan Science And Technology Agency ハンチンチン遺伝子の発現抑制
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
EP1735443A2 (en) 2004-04-14 2006-12-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
PL1945779T3 (pl) 2005-10-20 2013-08-30 Uniqure Ip Bv Ulepszone wektory AAV produkowane w komórkach owadzich
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
CA2662704A1 (en) 2006-07-07 2008-01-10 University Of Massachusetts Rna silencing compositions and methods for the treatment of huntington's disease
WO2008134646A2 (en) * 2007-04-26 2008-11-06 University Of Iowa Research Foundation Rna interference suppression of neurodegenerative diseases and methods of use thereof
US8258286B2 (en) * 2007-04-26 2012-09-04 University Of Iowa Research Foundation Reduction of off-target RNA interference toxicity
CN101868547B (zh) 2007-07-26 2016-03-16 尤尼克尔Ip股份有限公司 包含具有差别密码子偏性的重复编码序列的杆状病毒载体
AU2009215987B2 (en) 2008-02-19 2015-01-22 Uniqure Ip B.V. Optimisation of expression of parvoviral rep and cap proteins in insect cells
CN102439136A (zh) * 2009-03-26 2012-05-02 加州大学校董 产生用于疾病修饰的抑制性rna的间充质干细胞
CN107083400A (zh) * 2009-05-02 2017-08-22 建新公司 神经退行性疾病的基因治疗
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
PT2561078T (pt) * 2010-04-23 2018-12-03 Cold Spring Harbor Laboratory Sharn com uma conceção estrutural inovadora
CN102946908B (zh) * 2010-06-18 2015-04-22 Lsip基金运营联合公司 显性等位基因表达抑制剂
KR101961347B1 (ko) 2011-09-08 2019-03-25 유니큐어 아이피 비.브이. Aav 제조물로부터 오염 바이러스의 제거
CN103224556B (zh) * 2013-01-31 2015-04-15 清华大学 亨廷顿舞蹈症的靶位蛋白质及其编码基因和应用
HUE043842T2 (hu) * 2014-12-24 2019-09-30 Uniqure Ip Bv RNAi-indukált huntingtin gén szuppresszió

Also Published As

Publication number Publication date
SMT201900347T1 (it) 2019-07-11
LT3237618T (lt) 2019-07-10
KR102636633B1 (ko) 2024-02-13
DK3237618T3 (da) 2019-06-24
EP3237618A1 (en) 2017-11-01
BR112017013573A2 (pt) 2018-03-06
AU2015370903B2 (en) 2021-06-17
ES2732023T3 (es) 2019-11-20
US10174321B2 (en) 2019-01-08
AU2015370903A1 (en) 2017-07-20
IL252990B (en) 2021-09-30
SI3237618T1 (sl) 2019-09-30
CA2971920A1 (en) 2016-06-30
US11371044B2 (en) 2022-06-28
CA2971920C (en) 2024-05-07
JP6839094B2 (ja) 2021-03-03
CO2017007335A2 (es) 2018-01-05
TR201908969T4 (tr) 2019-07-22
WO2016102664A1 (en) 2016-06-30
HK1246344B (zh) 2020-01-10
CN108064292B (zh) 2021-05-04
PT3237618T (pt) 2019-07-04
CY1121733T1 (el) 2020-07-31
US20230119344A1 (en) 2023-04-20
KR20170120572A (ko) 2017-10-31
RS58862B1 (sr) 2019-07-31
EP3540063A1 (en) 2019-09-18
CN108064292A (zh) 2018-05-22
US20170355989A1 (en) 2017-12-14
US20190144860A1 (en) 2019-05-16
EP3237618B1 (en) 2019-05-22
PL3237618T3 (pl) 2019-09-30
JP2018502601A (ja) 2018-02-01
MX2017008500A (es) 2018-02-01
US10767180B2 (en) 2020-09-08
HRP20190992T1 (hr) 2019-09-20
HUE043842T4 (hu) 2019-08-28
JP2021000136A (ja) 2021-01-07
EA037696B1 (ru) 2021-05-12
NZ733296A (en) 2021-10-29
US20200339992A1 (en) 2020-10-29
IL252990A0 (en) 2017-08-31
EA201791417A1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
HK1246344B (zh) Rnai誘發的亨廷頓基因抑制
HK1247641A1 (zh) 變體RNAi
IL250448A0 (en) Modified double helix RNA materials
ZA201607100B (en) Frequency response
SG11201606379UA (en) Aptamer construct
IL249254B (en) Gene expression system
GB201517285D0 (en) Stabilizer arrangement
GB201408823D0 (en) Demulsifiers
IL246956A0 (en) targeted therapies
IL257500A (en) Altered cullin1 gene
GB201621449D0 (en) Frequency-domain denoising
IL248812A0 (en) Very effective stabilizer
SG11201702844VA (en) Photobioreactor
GB2547614B (en) Stabilizer
SG11201700652PA (en) Modified antimir-138 oligonucleotides
GB201608944D0 (en) Gene Tharapy
AU5592P (en) Lanmichigan Mandevilla boliviensis x sanderi
GB201410599D0 (en) Sensitizers
IL230329A0 (en) croc sponge
GB201403353D0 (en) Novel oligonucleotides
GB201403087D0 (en) Novel oligonucleotides
GB201407865D0 (en) Nucleases